Skip to contentpdufa.bio

SCY-770

Page updated ·next FDA decision on the calendar ·Data as of Nov 21, 2026 10:10 PM ET

SCY-770 is a Scynexis Inc program in autosomal dominant polycystic kidney disease (ADPKD). Its next catalyst is a Readout in Q4 2027.

SCYX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Autosomal dominant polycystic kidney disease (ADPKD). Sponsor: Scynexis Inc (SCYX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027SCYX

Questions

When is SCY-770's next FDA decision or readout?

The next tracked catalyst for SCY-770 is a Readout in Q4 2027.

What happened at SCY-770's most recent FDA decision?

No FDA decision for SCY-770 is in our archive yet.

What is SCY-770 used for?

In our records SCY-770 is under review or in development for Autosomal dominant polycystic kidney disease (ADPKD).

Who makes SCY-770?

Scynexis Inc (SCYX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.